ZAI LAB ANNOUNCES NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF AUGTYRO™ (REPOTRECTINIB) FOR PATIENTS WITH NTRK-POSITIVE SOLID TUMORS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.